Recent Updates — CYDY

The Board of Directors appointed Robert E. Hoffman as Chief Executive Officer effective October 20, 2026, succeeding Dr. Jacob P. Lalezari who resigned from the role and will remain with the company as Head of Research and Translational Sciences. Mr. Hoffman, previously the CFO, also continues to serve as principal accounting officer. His compensation includes a $525,000 annual base salary, a 50% bonus target, and a grant of 2,500,000 stock options. CytoDyn is a clinical-stage oncology company advancing leronlimab, a monoclonal antibody for solid-tumor indications.